Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Eur J Cancer. 2012 Jun 2;48(18):3488–3498. doi: 10.1016/j.ejca.2012.04.020

Figure 1. Effects of the c-Src inhibitor on ER positive wild-type cell lines.

Figure 1

1A. Blocking c-Src phosphorylation in ER positive wild-type cell lines by PP2. ER positive wild-type cells were treated with PP2 (5μM) in estrogenized medium at time points as indicated and cell lysates were harvested. Phosphorylated c-Src was detected by immunoblotting with primary antibody. Immunoblotting for total c-Src was used for loading control. 1B. Inhibitory effects of PP2 on wild-type ER positive cells. Wild-type ER positive cells were seeded in 24-well plates in triplicate in estrogenized medium. After one day, the cells were treated with vehicle (0.1%DMSO) and PP2 (5μM) respectively. The cells were harvested after 7 days treatment and total DNA was determined using a DNA fluorescence quantitation kit. 1C. Signaling pathways changes in ER positive wild-type cells after PP2 treatment. Cell lysates were harvested as above. Phosphorylated MAPK and Akt were examined by immunoblotting with primary antibodies. Immunoblotting for total MAPK and Akt were used for loading controls.